Cargando…

Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study

BACKGROUND: The primary aim of this study was to compare survival from neoadjuvant chemoradiotherapy plus surgery (NCRS) versus neoadjuvant chemotherapy plus surgery (NCS) for the treatment of esophageal or junctional adenocarcinoma. The secondary aims were to compare pathological effects, short-ter...

Descripción completa

Detalles Bibliográficos
Autores principales: Markar, S. R., Noordman, B. J., Mackenzie, H., Findlay, J. M., Boshier, P. R., Ni, M., Steyerberg, E. W., van der Gaast, A., Hulshof, M. C. C. M., Maynard, N., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., Reynolds, J. V., Van Lanschot, J. J. B., Hanna, G. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391716/
https://www.ncbi.nlm.nih.gov/pubmed/28039180
http://dx.doi.org/10.1093/annonc/mdw560
_version_ 1783229327142289408
author Markar, S. R.
Noordman, B. J.
Mackenzie, H.
Findlay, J. M.
Boshier, P. R.
Ni, M.
Steyerberg, E. W.
van der Gaast, A.
Hulshof, M. C. C. M.
Maynard, N.
van Berge Henegouwen, M. I.
Wijnhoven, B. P. L.
Reynolds, J. V.
Van Lanschot, J. J. B.
Hanna, G. B.
author_facet Markar, S. R.
Noordman, B. J.
Mackenzie, H.
Findlay, J. M.
Boshier, P. R.
Ni, M.
Steyerberg, E. W.
van der Gaast, A.
Hulshof, M. C. C. M.
Maynard, N.
van Berge Henegouwen, M. I.
Wijnhoven, B. P. L.
Reynolds, J. V.
Van Lanschot, J. J. B.
Hanna, G. B.
author_sort Markar, S. R.
collection PubMed
description BACKGROUND: The primary aim of this study was to compare survival from neoadjuvant chemoradiotherapy plus surgery (NCRS) versus neoadjuvant chemotherapy plus surgery (NCS) for the treatment of esophageal or junctional adenocarcinoma. The secondary aims were to compare pathological effects, short-term mortality and morbidity, and to evaluate the effect of lymph node harvest upon survival in both treatment groups. METHODS: Data were collected from 10 European centers from 2001 to 2012. Six hundred and eight patients with stage II or III oesophageal or oesophago-gastric junctional adenocarcinoma were included; 301 in the NCRS group and 307 in the NCS group. Propensity score matching and Cox regression analyses were used to compensate for differences in baseline characteristics. RESULTS: NCRS resulted in significant pathological benefits with more ypT0 (26.7% versus 5%; P < 0.001), more ypN0 (63.3% versus 32.1%; P < 0.001), and reduced R1/2 resection margins (7.7% versus 21.8%; P < 0.001). Analysis of short-term outcomes showed no statistically significant differences in 30-day or 90-day mortality, but increased incidence of anastomotic leak (23.1% versus 6.8%; P < 0.001) in NCRS patients. There were no statistically significant differences between the groups in 3-year overall survival (57.9% versus 53.4%; Hazard Ratio (HR)= 0.89, 95%C.I. 0.67-1.17, P = 0.391) nor disease-free survival (52.9% versus 48.9%; HR = 0.90, 95%C.I. 0.69-1.18, P = 0.443). The pattern of recurrence was also similar (P = 0.660). There was a higher lymph node harvest in the NCS group (27 versus 14; P < 0.001), which was significantly associated with a lower recurrence rate and improved disease free survival within the NCS group. CONCLUSION: The survival differences between NCRS and NCS maybe modest, if present at all, for the treatment of locally advanced esophageal or junctional adenocarcinoma. Future large-scale randomized trials must control and monitor indicators of the quality of surgery, as the extent of lymphadenectomy appears to influence prognosis in patients treated with NCS, from this large multi-center European study.
format Online
Article
Text
id pubmed-5391716
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-53917162017-04-24 Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study Markar, S. R. Noordman, B. J. Mackenzie, H. Findlay, J. M. Boshier, P. R. Ni, M. Steyerberg, E. W. van der Gaast, A. Hulshof, M. C. C. M. Maynard, N. van Berge Henegouwen, M. I. Wijnhoven, B. P. L. Reynolds, J. V. Van Lanschot, J. J. B. Hanna, G. B. Ann Oncol Original Articles BACKGROUND: The primary aim of this study was to compare survival from neoadjuvant chemoradiotherapy plus surgery (NCRS) versus neoadjuvant chemotherapy plus surgery (NCS) for the treatment of esophageal or junctional adenocarcinoma. The secondary aims were to compare pathological effects, short-term mortality and morbidity, and to evaluate the effect of lymph node harvest upon survival in both treatment groups. METHODS: Data were collected from 10 European centers from 2001 to 2012. Six hundred and eight patients with stage II or III oesophageal or oesophago-gastric junctional adenocarcinoma were included; 301 in the NCRS group and 307 in the NCS group. Propensity score matching and Cox regression analyses were used to compensate for differences in baseline characteristics. RESULTS: NCRS resulted in significant pathological benefits with more ypT0 (26.7% versus 5%; P < 0.001), more ypN0 (63.3% versus 32.1%; P < 0.001), and reduced R1/2 resection margins (7.7% versus 21.8%; P < 0.001). Analysis of short-term outcomes showed no statistically significant differences in 30-day or 90-day mortality, but increased incidence of anastomotic leak (23.1% versus 6.8%; P < 0.001) in NCRS patients. There were no statistically significant differences between the groups in 3-year overall survival (57.9% versus 53.4%; Hazard Ratio (HR)= 0.89, 95%C.I. 0.67-1.17, P = 0.391) nor disease-free survival (52.9% versus 48.9%; HR = 0.90, 95%C.I. 0.69-1.18, P = 0.443). The pattern of recurrence was also similar (P = 0.660). There was a higher lymph node harvest in the NCS group (27 versus 14; P < 0.001), which was significantly associated with a lower recurrence rate and improved disease free survival within the NCS group. CONCLUSION: The survival differences between NCRS and NCS maybe modest, if present at all, for the treatment of locally advanced esophageal or junctional adenocarcinoma. Future large-scale randomized trials must control and monitor indicators of the quality of surgery, as the extent of lymphadenectomy appears to influence prognosis in patients treated with NCS, from this large multi-center European study. Oxford University Press 2017-03 2016-10-25 /pmc/articles/PMC5391716/ /pubmed/28039180 http://dx.doi.org/10.1093/annonc/mdw560 Text en © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Markar, S. R.
Noordman, B. J.
Mackenzie, H.
Findlay, J. M.
Boshier, P. R.
Ni, M.
Steyerberg, E. W.
van der Gaast, A.
Hulshof, M. C. C. M.
Maynard, N.
van Berge Henegouwen, M. I.
Wijnhoven, B. P. L.
Reynolds, J. V.
Van Lanschot, J. J. B.
Hanna, G. B.
Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study
title Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study
title_full Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study
title_fullStr Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study
title_full_unstemmed Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study
title_short Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study
title_sort multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391716/
https://www.ncbi.nlm.nih.gov/pubmed/28039180
http://dx.doi.org/10.1093/annonc/mdw560
work_keys_str_mv AT markarsr multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT noordmanbj multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT mackenzieh multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT findlayjm multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT boshierpr multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT nim multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT steyerbergew multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT vandergaasta multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT hulshofmccm multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT maynardn multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT vanbergehenegouwenmi multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT wijnhovenbpl multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT reynoldsjv multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT vanlanschotjjb multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy
AT hannagb multimodalitytreatmentforesophagealadenocarcinomamulticenterpropensityscorematchedstudy